Table 3. Evaluation bias between central versus local assessments.

Summary/subgroup	ORR (Exp/Con)					DCR (Exp/Con)
	S (n)	OR (95% CI)	P†	I2‡§ (%)		S (n)	OR (95% CI)	Pa	I2‡§ (%)
Summary	28	1.02 (0.97–1.07)	0.42	0		16	0.98 (0.93–1.03)	0.37	0
Mask
Open	22	1.03 (0.98–1.09)	0.23	30		12	0.97 (0.91–1.02)	0.25	0
Blind	6	0.95 (0.84–1.08)	0.43			4	1.01 (0.91–1.13)	0.79
Sample size
> median (618.5)	14	1.00 (0.94–1.06)	0.99	1		10	0.96 (0.91–1.02)	0.21	0
< median (618.5)	14	1.05 (0.97–1.14)	0.20			6	1.03 (0.92–1.15)	0.63
Tumor type
NSCLC	8	1.01 (0.93–1.10)	0.81	0		4	1.01 (0.91–1.12)	0.85	0
Breast	7	1.08 (0.98–1.20)	0.13			5	0.98 (0.89–1.07)	0.62
Renal-cell	6	1.01 (0.91–1.12)	0.86			4	0.95 (0.87–1.05)	0.35
Ovarian	3	0.98 (0.85–1.12)	0.72			1	0.91 (0.77–1.09)	0.32
Others	4	1.00 (0.86–1.15)	0.99			2	1.04 (0.83–1.30)	0.73
Primary endpoint
Central-assessed	16	1.04 (0.98–1.10)	0.22	50		10	0.97 (0.91–1.04)	0.37	0
Others	7	0.92 (0.83–1.03)	0.16			5	0.99 (0.90–1.08)	0.76
Local-assessed	5	1.08 (0.94–1.24)	0.28			1	0.99 (0.80–1.23)	0.93
Primary outcome
Positive	18	1.04 (0.98–1.11)	0.23	0		10	0.99 (0.93–1.06)	0.76	0
Indeterminate	1	1.10 (0.61–1.95)	0.76			1	0.98 (0.68–1.42)	0.92
Negative	9	0.99 (0.92–1.07)	0.84			5	0.96 (0.88–1.04)	0.30

^†, P value for the comparison between central and local assessments; P<0.05 indicated significant discrepancy; ^‡, I² in summary outcome was for heterogeneity of data synthesis; ^§, I² in subgroup was for subgroup difference, representing the interaction effects between the elements of each subgroup factor. Exp, experimental arm; Con, control arm; ORR, objective response rate; DCR, disease control rate; OR, odds ratio; S, study.